Cayston meets endpoint

Gilead Sciences Inc. (NASDAQ:GILD) said Cayston aztreonam lysine met the co-primary endpoint of non-inferiority to inhaled tobramycin in the Phase III Study 205-0110 trial to treat pulmonary Pseudomonas aeruginosa infections in patients with cystic fibrosis. Cayston was non-inferior to tobramycin in mean percent change from baseline in percent predicted FEV1 at day 28 (8.35% vs. 0.55% increases, p=0.0001). Data for the other co-primary endpoint of the open-label, U.S. and European trial in 268 patients -- superiority to inhaled tobramycin in mean change in percent predicted FEV1 across three treatment cycles -- will be presented later this year. Data were presented at the European Cystic Fibrosis meeting in Valencia. ...